Original articleHemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: Clinical and epidemiologic observations
References (35)
- et al.
Hemolytic-uremic syndrome: current concepts and management
Pediatr Clin North Am
(1982) - et al.
Sporadic cases of hemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools
Lancet
(1983) Exact and asymptomatic methods for the combination of 2×2 tables
Comput Biomed Res
(1975)- et al.
Hemolytic uremic syndrome and diarrhea associated with Escherichia coli O157:H7 in a day care center
J Pediatr
(1986) - et al.
Hospital-acquired Escherichia coli O157:H7 associated haemolytic uraemic syndrome in a nurse
Lancet
(1988) - et al.
Risk factors for development of hemolytic-uremic syndrome during shigellosis
J Pediatr
(1987) - et al.
Neutrophil-mediated endothelial cell injury in haemolytic uraemic syndrome
Lancet
(1989) - et al.
Shigella dysenteriae type 1 infections in U.S. travellers to Mexico, 1988
Lancet
(1989) - et al.
Growth of Escherichia coli in the presence of trimethoprim-sulfamethoxazole facilitates detection of Shiga-like toxin producing strains by colony blot assay
FEMS Microbiol Lett
(1986) - et al.
Hamolytisch-uramische Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hamolytischen Anamien
Schweiz Med Wochenschr
(1955)
Hemolytic uremic syndrome—then and now
N Engl J Med
The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing strains of Escherichia coli
J Infect Dis
Further evidence associating hemolytic uremic syndrome with infection by verotoxin-producing Escherichia coli O157:H7
J Infect Dis
Escherichia coli O157:H7 as the predominant pathogen associated with the hemolytic uremic syndrome: a prospective study in the Pacific Northwest
Pediatrics
Haemorrhagic colitis and haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli (VTEC) in England and Wales
Sporadic occurrence of hemorrhagic colitis associated with Escherichia coli O157:H7 in Newfoundland
Can Med Assoc J
Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7
Ann Intern Med
Cited by (239)
Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview
2019, Journal of InfectionCitation Excerpt :In vivo studies have demonstrated that, while some benefit may exist from the early administration of TMP/SMX, it is soon lost, with HUS ensuing if the drug is administered three days after the inoculation of bacteria.30 Nevertheless, quite a few clinical studies concerning TMP/SMX are available, the majority of which report that its use increases the incidence of HUS8,49,55,57 and even more so if administered during the first 72 h after the onset of symptoms.57 Only one study reported that the administration of TMP/SMX for more than 24 h in patients with STEC O157:H7 infection prevented its progression to HUS,59 while two others concluded that administration of sulfonamides38 or TMP/SMX33 had no effect in the occurrence of HUS.
Effect of lactoferrin on release and bioactivity of Shiga toxins from different Escherichia coli O157:H7 strains
2017, Veterinary MicrobiologyCitation Excerpt :Some studies associate the administration of antibiotics with higher risk for HUS as well as with longer duration of diarrhoea and/or bloody diarrhoea. Patients treated with trimethoprim/sulphamethoxazole tended to have longer duration of diarrhoea and bloody diarrhoea and were more likely to develop HUS than patients who did not receive an antibiotic, although this negative effect was not seen for ampicillin treatment (Pavia et al., 1990; Ostroff et al., 1989). Antibiotics affect the release of Stx, but do not cause degradation of the toxin.
Inhibition of verotoxin (VT) 2 absorption into systemic blood from intestine by repeated administration of bovine immune colostral antibody against VT2 in mice
2015, Journal of Microbiology, Immunology and InfectionA role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection
2015, International Journal of Antimicrobial AgentsCitation Excerpt :They then cause direct damage to endothelial cells as well as indirect damage by the activation of neutrophils [15]. Pavia et al. [11] found that a patient's illness from E. coli O157 peaked on the fourth day. From these observations, it is suggested that in order to prevent the development of HUS in patients with E. coli O157, patients need to be treated during the early period of the illness.
Screening of the novel colicinogenic gram-negative rods against pathogenic Escherichia coli O157:H7
2015, Indian Journal of Medical Microbiology